profit
slide
at
india
dr
reddi
profit
at
indian
drugmak
dr
reddi
fell
a
research
cost
rose
and
sale
flag
the
firm
said
it
profit
were
m
rupe
â£
for
the
three
month
to
decemb
on
sale
which
fell
to
bn
rupe
dr
reddi
ha
built
it
reput
on
produc
gener
version
of
bignam
pharmaceut
product
but
competit
ha
intensifi
and
the
firm
and
the
compani
is
short
on
new
product
launch
the
most
recent
wa
the
annouc
in
decemb
that
it
had
won
exclus
market
right
for
a
gener
version
of
the
famou
antidepress
prozac
from
it
maker
eli
lilli
it
also
lost
a
key
court
case
in
march
ban
it
from
sell
a
version
of
pfizer
popular
hypertens
drug
norvasc
in
the
u
research
and
develop
of
new
drug
is
continu
apac
with
rd
spend
rise
to
m
rupe
a
key
caus
of
the
decreas
in
profit
alongsid
the
fall
in
sale
patent
on
a
number
of
wellknown
product
are
due
to
run
out
in
the
near
futur
repres
an
opportun
for
dr
reddi
whose
share
are
list
in
new
york
and
other
indian
gener
manufactur
sale
in
dr
reddi
gener
busi
fell
to
m
rupe
anoth
stapl
of
the
the
firm
busi
the
sale
of
ingredi
for
drug
also
perform
poorli
sale
were
down
more
than
from
the
previou
year
to
bn
rupe
in
the
face
of
strong
competit
both
at
home
and
in
the
u
and
europ
dr
reddi
indian
competitor
are
gather
strength
although
they
too
face
heavi
competit
pressur
